Immune Checkpoint Blockade in Hepatocellular Carcinoma: 2017 Update.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

35 citing papers in PubMed.

1. Debates and progress in the management of intermediate-stage (BCLC stage B) hepatocellular carcinoma.iLIVER · 2025
   Review
2. Role of Immunological Cells in Hepatocellular Carcinoma Disease and Associated Pathways.ACS pharmacology & translational science · 2023
   Review
3. Identification of a novel signature based on macrophage-related marker genes to predict prognosis and immunotherapeutic effects in hepatocellular carcinoma.Frontiers in oncology · 2023
   Article
4. Emerging Management Approach for the Adverse Events of Immunotherapy of Cancer.Molecules (Basel, Switzerland) · 2022
   Review
5. Hepatitis B Virus Reactivation in Cancer Patients Undergoing Immune Checkpoint Inhibitors Therapy: A Systematic Review.Journal of Cancer · 2022
   Review
6. Bioinformatics Profiling of Five Immune-Related lncRNAs for a Prognostic Model of Hepatocellular Carcinoma.Frontiers in oncology · 2021
   Article
7. Molecular Bases of Drug Resistance in Hepatocellular Carcinoma.Cancers · 2020
   Review
8. Nucleostemin Modulates Outcomes of Hepatocellular Carcinoma via a Tumor Adaptive Mechanism to Genomic Stress.Molecular cancer research : MCR · 2020
   Article
9. Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma.Cancers · 2020
   Review
10. A New Era in Systemic Therapy for Hepatocellular Carcinoma: Atezolizumab plus Bevacizumab Combination Therapy.Liver cancer · 2020
    Article
11. The promise of adoptive cellular immunotherapies in hepatocellular carcinoma.Oncoimmunology · 2020
    Review
12. Split chimeric antigen receptor-modified T cells targeting glypican-3 suppress hepatocellular carcinoma growth with reduced cytokine release.Therapeutic advances in medical oncology · 2020
    Article
13. Challenges in liver cancer and possible treatment approaches.Biochimica et biophysica acta. Reviews on cancer · 2020
    Review
14. An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis.Journal of visualized experiments : JoVE · 2019
    Article
15. Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.European radiology · 2019
    Review
16. Adjuvant therapy after radical surgery for hepatocellular carcinoma: still an unmet need.Hepatobiliary surgery and nutrition · 2019
    Article
17. Immuno-Oncology Therapy for Hepatocellular Carcinoma: Current Status and Ongoing Trials.Liver cancer · 2019
    Article
18. Liver damage related to immune checkpoint inhibitors.Hepatology international · 2019
    Review
19. Pembrolizumab for the Treatment of Hepatocellular Carcinoma.Liver cancer · 2019
    Article
20. Extracellular Vesicle-Based Therapeutic Targeting of β-Catenin to Modulate Anticancer Immune Responses in Hepatocellular Cancer.Hepatology communications · 2019
    Article

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.